Research Analysts’ Recent Ratings Changes for Biohaven (BHVN)

A number of research firms have changed their ratings and price targets for Biohaven (NYSE: BHVN):

• 11/3/2026 – Biohaven had its price target raised by Morgan Stanley from $19.00 to $21.00. They now have an “overweight” rating on the stock.
• 11/2/2026 – Biohaven was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/30/2026 – Biohaven had its price target raised by Canaccord Genuity Group from $21.00 to $32.00. They now have a “buy” rating on the stock.
• 10/24/2026 – Biohaven was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/23/2026 – Biohaven had its price target raised by Royal Bank Of Canada from $19.00 to $22.00. They now have a “sector perform” rating on the stock.
• 10/22/2026 – Biohaven was given a new $48.00 price target by Robert W. Baird.
• 10/8/2026 – Biohaven had its “strong-buy” rating reaffirmed by Raymond James Financial.
• 9/18/2026 – Biohaven had its “buy” rating reaffirmed by Citigroup.
• 9/10/2026 – Biohaven had its “neutral” rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
• 9/8/2026 – Biohaven was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $19.00 price target on the stock, down from $23.00.

Biohaven Price Performance

Shares of BHVN stock opened at $15.22 on Thursday. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 21.23. Biohaven Ltd. has a twelve month low of $7.48 and a twelve month high of $18.24. The company has a market cap of $2.30 billion, a P/E ratio of -3.94 and a beta of 1.36. The business has a fifty day simple moving average of $13.71 and a 200 day simple moving average of $12.30.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). On average, sell-side analysts forecast that Biohaven Ltd. will post -3.11 EPS for the current fiscal year.

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.